Merck, Inc.
🇵🇭Philippines
Sitagliptin Added-on to Insulin Study (0431-051)
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 641
- Registration Number
- NCT00395343
Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)
Phase 2
Completed
- Conditions
- RhinovirusAsthmaCommon ColdPicornavirus Infection
- Interventions
- Drug: Placebo to PleconarilDrug: Pleconaril
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 311
- Registration Number
- NCT00394914
Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin
Phase 2
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: NM283 plus Peg-IFNα-2a
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2010-06-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 114
- Registration Number
- NCT00395421
Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)
Phase 3
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 43
- Registration Number
- NCT00394589
Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)
Phase 3
Completed
- Conditions
- Hepatitis B
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1478
- Registration Number
- NCT00393523
Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea
Phase 3
Completed
- Conditions
- Acute Gastroenteritis in Adult Travelers
- Interventions
- Drug: PlaceboDrug: Prulifloxacin
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 282
- Registration Number
- NCT00392574
- Locations
- 🇺🇸
INC Research, New Hope, Pennsylvania, United States
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Phase 2
Completed
- Conditions
- GliomaAstrocytomaOligodendrogliomaGlioblastoma
- Interventions
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00392171
Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)
Phase 3
Completed
- Conditions
- Complicated Intra-Abdominal Infections
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT00389987
Effect of Rofecoxib and a Narcotic Analgesic to Treat Pain Following Arthroscopic Surgery (0966-179)(COMPLETED)
Phase 3
Completed
- Conditions
- Pain, Postoperative Arthroscopy
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 420
- Registration Number
- NCT00390260
A Study to Evaluate the Safety and Efficacy of an Investigational Drug in the Treatment of Postoperative Dental Pain (MK-2295-005)
Phase 2
Completed
- Conditions
- Tooth ExtractionPain, Postoperative
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 89
- Registration Number
- NCT00387140
© Copyright 2025. All Rights Reserved by MedPath